


Development of a Multi Analyte Method for the Screening of Products Marketed as Dietary Supplements

Christopher Beekman, Rahul Pawar

U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition



Introduction



https://www.fda.gov/files/DS_Homepage_header%20graphic.jpg

The dietary supplement market can be perceived by consumers as a safer and natural alternative to some conventional medicines to support bodily needs and functions. The market is diverse including a variety of dietary ingredients (e.g., vitamins, minerals, herbs, amino acids, and enzymes) which can be manufactured in many forms (e.g., tablets, capsules, softgels, powders, and liquids). Additionally, products marketed as dietary supplements may have unallowed ingredients, substitutions of an intended botanical ingredient, or the addition of adulterants such as active pharmaceutical ingredients. To assist in monitoring and to enforce regulations on the composition of products marketed as dietary supplements, this research will include the development and validation of a high-resolution mass spectrometry method for compound screening, identification, and quantification.

Objective

Developing a Desirable Method

1. Verify Ingredients
2. Detect Contaminants

- Simple and Direct Sample Preparation
Tablets, Capsules, Softgels, Liquids, Gummies, Powders, and Bars.
- Analytical Methodology
Liquid Chromatography - High Resolution Tandem Mass Spectrometry (LC-HRMS/MS)
- Untargeted Method
Support Market Surveillance
Suspect/Non-targeted screening
- Targeted Method
Analyte confirmation and quantitation

Surveillance Methods

Market Survey

Screening many products marketed as different supplement for a variety of know ingredients and the absence of contaminants and adulterants

For Cause

Screening of a specific product in response to a consumer complaint or adverse event report



Target Assignments

Targeting a specific class of products to support claimed ingredients or absence of adulterants

Database Curation

Untargeted Method Development

A compound library was curated through collaborations with the CFSAN Office of Regulatory Science (ORS), the CFSAN Office of Dietary Supplements Programs (ODSP), and the Office of Regulatory Affairs (ORA). The library was created in Compound Discoverer (Thermo) using the ChemSpider data available for each compound. After curation to remove redundancies in compound nomenclature, a total of 372 compounds remained including but not limited to dietary ingredients, adulterants, plant toxins and pharmaceuticals.


Targeted Method Development

A sub-set of library targets (Phase One) were selected for quantitation. Analytical figures of merit (e.g., accuracy, precision, selectivity) will be determined for 29 target compounds and compared for representative dietary supplement matrix types (tablet, capsule, softgel, powders, liquid, and gummy).

#	Structure	Name	Formula	Molecular Weight	RT [min]	AB #	Phase
351		vardenafil	C23 H32 N6 O4 S	488.22057	15.210	352	29
369		octopamine	C8 H11 N O2	153.07888	362	8	8
5		Sildenafil	C22 H30 N6 O4 S	474.20492	16.300	316	27
35		Caffeine	C8 H10 N4 O2	194.08038	8.980	72	4
18		Melatonin	C13 H16 N2 O2	232.12118	15.670	201	19
17		Serotonin	C10 H12 N2 O	176.09496	359	20	20

#	Structure	Name	Formula	Molecular Weight	RT [min]
4		Caffeine	C8 H10 N4 O2	194.08038	8.980
19		Melatonin	C13 H16 N2 O2	232.12118	15.670
20		Serotonin	C10 H12 N2 O	176.09496	1.970
27		Sildenafil	C22 H30 N6 O4 S	474.20492	16.300


Targeted Data



For confirmation of identity, the measured exact mass (± 5 ppm) of at least two structurally specific ions (precursor ion and one or more fragment ions) at the retention time of a comparison standard is required. Quantification is performed using an external solvent standard calibration.

Method Parameters

Experimental Sample Extraction




LC Method Parameters

- Vanquish Conditions:**
- Sample diluent: Acetonitrile (ACN):H₂O (50:50)
 - Column: ACQUITY PREMIER BEH Shield RP18, 1.7 µm VanGuard FIT 2.1 x 100 mm
 - Column Temperature: 30°C
 - Mobile Phase A: 0.1% formic acid in H₂O
 - Mobile Phase B: 0.1% formic acid in acetonitrile
 - Flow rate: 300 µL/min
 - 2 µL injection


MS Method Parameters

- Orbitrap ID-X MS Conditions:**
- Full MS
 - ESI
 - Positive mode
 - Resolution 60,000
 - AGC Target: 4e6
 - Scan Range: 80 to 800 m/z
 - ddMS² (top intensity)
 - Resolution: 30,000
 - AGC Target: 5e5
 - Scan Range: 80 to 800 m/z
 - Collision Energy mode: Assisted (20, 35, 60)
 - ddMS² (Inclusion List)
 - Resolution: 30,000
 - AGC Target: 5e5
 - Scan Range: 80 to 800 m/z
 - Collision Energy mode: Assisted (20, 35, 60)

Untargeted Data Processing



Compound Discoverer Software (Thermo) was used to process the data for untargeted screening. A representative processing workflow is displayed, including an illustration for the identification of a melatonin in as standard solution and in different fortified matrix samples.



Conclusions

Current Progress

- Compound database of 372 compounds for untargeted screening has been curated
- 29 (Phase One) compounds have been selected and tested by targeted analysis and will undergo single laboratory validation
- A multi-phase liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) method has been developed to screen for known ingredients and contaminants in products marketed as dietary supplements and quantify positive compound identifications.
- Current efforts are exploring improved or adaptive extraction method based on serving size to reduce the effects of dilution

Future Directions

- Validate data processing method for compound identification
- Extend targeted method to phase 2 compounds of interest. Single laboratory validate.
- Evaluate method performance in blinded test samples.

Acknowledgements

- Office of Regulatory Science (ORS)
 - Christine Parker
 - Rahul Pawar
- Office of Regulatory Affairs (ORA)
 - Erica Bakota
 - Douglas Monroe
- Office of Dietary Supplements Programs (ODSP)